Microbiome specialist Enterobiotix Ltd. is in the throes of raising a new round of funding for a phase IIb trial after reporting positive results from the phase IIa study of EBX-102-02, an oral therapy for irritable bowel syndrome (IBS).
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder where visceral hypersensitivity (VH), which causes discomfort and negatively impacts the quality of life, is influenced by stressful events. In recent years, the use of bifidobacteria and lactic acid bacteria has shown anti-VH efficacy.
Researchers from Johns Hopkins University and Lieber Institute Inc. have synthesized peripherally and luminally restricted inhibitors of the serotonin transporter (SERT) reported to be useful for disorders of gastrointestinal motility, including the treatment of irritable bowel syndrome (IBS).
According to a new study published in the July 27, 2022, issue of ScienceTranslationalMedicine, a lower intake of fermentable carbohydrates produces changes in the intestinal microbiota that decrease histamine production reducing chronic abdominal pain in patients with irritable bowel syndrome.
The rising tide of digital therapeutics approved and funded in the U.S. raised the outlook for Mahana Therapeutics Inc. and Freespira Inc. as both companies announced good news. Mahana's prescription digital therapeutic for gastrointestinal conditions, Parallel, received premarket authorization from the U.S. FDA and Freespira, formerly Palo Alto Health Sciences Inc., raised $10 million for its digital therapeutic for panic attacks, panic disorder and post-traumatic stress disorder.
